NCT06108479 is a Phase 1 clinical trial of DF6215 in Solid Tumor, Adult, sponsored by Dragonfly Therapeutics.

Who is sponsoring NCT06108479?

NCT06108479 is sponsored by Dragonfly Therapeutics.

What drugs are being tested in NCT06108479?

Interventions in NCT06108479: DF6215, pembrolizumab, KEYTRUDA®.

What condition does NCT06108479 study?

NCT06108479 studies Solid Tumor, Adult, Solid Tumor Cancer.

Is NCT06108479 still recruiting?

NCT06108479 is currently completed. Last updated 18 March 2026.

Last reviewed 2026-03-18 · How we verify

NCT06108479

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of DF6215 in Patients With Advanced Solid Tumors

Completed Phase 1 Last updated 18 March 2026

What this trial tests

Phase 1 trial testing DF6215 in Solid Tumor, Adult in 35 participants. Completed in 4 December 2025.

Timeline

28 November 2023

Primary endpoint
4 December 2025

4 December 2025

Quick facts

Lead sponsor	Dragonfly Therapeutics
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	28 November 2023
Primary completion	4 December 2025
Estimated completion	4 December 2025
Sites	21 locations across France, United States, Australia

Drugs / interventions tested

DF6215 — full drug profile →
pembrolizumab (pembrolizumab) — full drug profile →
KEYTRUDA®

Conditions studied

Solid Tumor, Adult — all drugs for Solid Tumor, Adult →
Solid Tumor Cancer — all drugs for Solid Tumor Cancer →

Sponsor

Dragonfly Therapeutics — full company profile →

Who can join

18 and older, any sex, with Solid Tumor, Adult or Solid Tumor Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase I/Ib, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 Monotherapy and in Combination Therapy in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors; is designed to assess the safety, tolerability, and preliminary efficacy of DF6215 alone or in combination with pembrolizumab in patients with advanced solid tumors. The study is open-label, meaning both participants and investigators are aware of the treatment being administered.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting γc family cytokines with biologics: current status and future prospects.
Bick F, Blanchetot C, Lambrecht BN, Schuijs MJ. · · 2025 · cited 5× · PMID 39967341 · DOI 10.1080/19420862.2025.2468312
The promise of immunotherapy in the treatment of sarcoma: A state-of-the-art review of practice changing research and future directions.
Kulkarni NJ, Kelly CM, Bartlett EK. · · 2026 · PMID 42172443 · DOI 10.1080/21645515.2026.2674185
Advancements in the utilization of immune checkpoint inhibitors for the treatment of gynecological tumors.
Su Z, Zhang X, Xu J, Shen Y. · · 2026 · PMID 41983132 · DOI 10.3389/fimmu.2026.1686568
DF6215, an α-optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activity.
Stockmann AP, Vincent S, Herschelman L, Huang CS, et al · · 2026 · PMID 41468896 · DOI 10.1016/j.xcrm.2025.102518

Verify or expand the search:

Other recruiting trials for Solid Tumor, Adult

Currently open trials in the same condition.

NCT07139990 — Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) · Phase 1 · recruiting
NCT06398418 — R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients · Phase 1 · recruiting
NCT06682793 — A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor · Phase 1, PHASE2 · recruiting
NCT07137195 — Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei) · NA · active not recruiting
NCT06714617 — Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting

Other Dragonfly Therapeutics trials

Trials by the same sponsor.

NCT05597839 — Study of DF9001 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · completed
NCT04423029 — A Study of DF6002 Alone and in Combination With Nivolumab · Phase 1 · completed
NCT04143711 — Study of DF1001 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06108479 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dragonfly Therapeutics
Last refreshed: 18 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06108479.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing